User login
On your mark, get set, GO! The NetWorks Challenge is now underway!
We are so excited to once again host the NetWorks Challenge. During the next 3 months, you have the opportunity to be a Champion and make a donation to the CHEST Foundation. Every time you contribute, you can designate a NetWork of your choice to benefit from your gift. Each NetWork is eligible to receive travel grants to CHEST 2019 based on the amount raised. Last year, we more than doubled the number of early career clinician travel grants to attend CHEST 2018. This year, we want to raise the bar again. Don’t delay, make a donation today by visiting Chestfoundation.org/donate and be a Champion for your NetWork!
Length: This year, the NetWorks Challenge will span 3 months. Contributions made between April 1 and June 30 count toward your NetWork’s fundraising total! Just be sure to list your NetWork when making your contribution on chestfoundation.org/donate. Additionally, any contributions made to the CHEST Foundation during your membership renewal will count toward your NetWorks total amount raised - no matter when your membership is up for renewal. Contributions made in this manner after June 30 will count toward your Network’s 2020 amount raised.
Each month has a unique theme related to CHEST, so be sure to watch our social media profiles to engage with us and each other during the drive.
Prizes: This year, every NetWork is eligible to receive travel grants to CHEST 2019 in New Orleans based on the amount raised by the NetWork. Our final winners – the NetWork with the highest amount raised and the NetWork with the highest participation rate, will each receive two additional travel grants to CHEST 2019. Plus, the NetWork with the highest amount raised over the course of the challenge receives an additional prize – a seat in a CHEST Live Learning course of the winner’s choosing, offered at CHEST’s Innovation, Simulation, and Training Center in Glenview, Illinois.
Visit chestfoundation.org/nc for more detailed information!
We are so excited to once again host the NetWorks Challenge. During the next 3 months, you have the opportunity to be a Champion and make a donation to the CHEST Foundation. Every time you contribute, you can designate a NetWork of your choice to benefit from your gift. Each NetWork is eligible to receive travel grants to CHEST 2019 based on the amount raised. Last year, we more than doubled the number of early career clinician travel grants to attend CHEST 2018. This year, we want to raise the bar again. Don’t delay, make a donation today by visiting Chestfoundation.org/donate and be a Champion for your NetWork!
Length: This year, the NetWorks Challenge will span 3 months. Contributions made between April 1 and June 30 count toward your NetWork’s fundraising total! Just be sure to list your NetWork when making your contribution on chestfoundation.org/donate. Additionally, any contributions made to the CHEST Foundation during your membership renewal will count toward your NetWorks total amount raised - no matter when your membership is up for renewal. Contributions made in this manner after June 30 will count toward your Network’s 2020 amount raised.
Each month has a unique theme related to CHEST, so be sure to watch our social media profiles to engage with us and each other during the drive.
Prizes: This year, every NetWork is eligible to receive travel grants to CHEST 2019 in New Orleans based on the amount raised by the NetWork. Our final winners – the NetWork with the highest amount raised and the NetWork with the highest participation rate, will each receive two additional travel grants to CHEST 2019. Plus, the NetWork with the highest amount raised over the course of the challenge receives an additional prize – a seat in a CHEST Live Learning course of the winner’s choosing, offered at CHEST’s Innovation, Simulation, and Training Center in Glenview, Illinois.
Visit chestfoundation.org/nc for more detailed information!
We are so excited to once again host the NetWorks Challenge. During the next 3 months, you have the opportunity to be a Champion and make a donation to the CHEST Foundation. Every time you contribute, you can designate a NetWork of your choice to benefit from your gift. Each NetWork is eligible to receive travel grants to CHEST 2019 based on the amount raised. Last year, we more than doubled the number of early career clinician travel grants to attend CHEST 2018. This year, we want to raise the bar again. Don’t delay, make a donation today by visiting Chestfoundation.org/donate and be a Champion for your NetWork!
Length: This year, the NetWorks Challenge will span 3 months. Contributions made between April 1 and June 30 count toward your NetWork’s fundraising total! Just be sure to list your NetWork when making your contribution on chestfoundation.org/donate. Additionally, any contributions made to the CHEST Foundation during your membership renewal will count toward your NetWorks total amount raised - no matter when your membership is up for renewal. Contributions made in this manner after June 30 will count toward your Network’s 2020 amount raised.
Each month has a unique theme related to CHEST, so be sure to watch our social media profiles to engage with us and each other during the drive.
Prizes: This year, every NetWork is eligible to receive travel grants to CHEST 2019 in New Orleans based on the amount raised by the NetWork. Our final winners – the NetWork with the highest amount raised and the NetWork with the highest participation rate, will each receive two additional travel grants to CHEST 2019. Plus, the NetWork with the highest amount raised over the course of the challenge receives an additional prize – a seat in a CHEST Live Learning course of the winner’s choosing, offered at CHEST’s Innovation, Simulation, and Training Center in Glenview, Illinois.
Visit chestfoundation.org/nc for more detailed information!
Five things to do near the convention center in NOLA
While CHEST 2019 will have your days busy, don’t forget to find time to explore entertaining, cultural, and historic places around New Orleans. Grab your friends and colleagues for some fun, and try out a few of these places!
1. House of Blues New Orleans
If you’re already heading to the city known for jazz and blues, there’s no better place to experience that than the House of Blues New Orleans. Enjoy live music and great food under one roof. Be sure to check the House of Blues website as the annual meeting draws nearer to see which concerts and events will be happening in October.
2. Audubon Aquarium of the Americas
Located just north of the convention center, head over to the Audubon Aquarium of the Americas. During the fall and winter months, the aquarium has less traffic, which allows you to take in all the animals and exhibits at your own pace. See exhibits like the Great Maya Reef, a walk-through tunnel into a submerged Maya city of the Yucatan peninsula; the penguins, sea otters, or the sharks and rays in the 400,000-gallon Gulf of Mexico Exhibit.
Hours: Monday - Sunday | 10 AM - 5 PM
3. Ogden Museum of Southern Art
Less than 5 minutes from the convention center, the Ogden Museum of Southern Art holds the largest and most comprehensive collection of southern art, including visual art, music, literature, and culinary heritage. If you’re in the city before or after the annual meeting, catch a guided tour on a Thursday afternoon. Tours are free with admission into the museum. Check their website for museum hours.
4. Escape My Room
Who doesn’t love a good escape room? At Escape My Room, look for clues and hints to help the DeLaporte family as you’re transported through history into the DeLaporte Family Museum. Bring your family or team in a group of up to eight, depending on the room, and see if you can solve the mystery.
5. A walking tour of the Garden District
Take a cable car a few stops to the Garden District, a historic neighborhood in New Orleans. This picturesque neighborhood showcases plantation-style mansions, streets separated by stretches of green parks, and the historic Lafayette Cemetery No. 1 and cable car line that runs along St. Charles Avenue. There are guided tours available, but you can also choose to take a self-tour of the area.
While CHEST 2019 will have your days busy, don’t forget to find time to explore entertaining, cultural, and historic places around New Orleans. Grab your friends and colleagues for some fun, and try out a few of these places!
1. House of Blues New Orleans
If you’re already heading to the city known for jazz and blues, there’s no better place to experience that than the House of Blues New Orleans. Enjoy live music and great food under one roof. Be sure to check the House of Blues website as the annual meeting draws nearer to see which concerts and events will be happening in October.
2. Audubon Aquarium of the Americas
Located just north of the convention center, head over to the Audubon Aquarium of the Americas. During the fall and winter months, the aquarium has less traffic, which allows you to take in all the animals and exhibits at your own pace. See exhibits like the Great Maya Reef, a walk-through tunnel into a submerged Maya city of the Yucatan peninsula; the penguins, sea otters, or the sharks and rays in the 400,000-gallon Gulf of Mexico Exhibit.
Hours: Monday - Sunday | 10 AM - 5 PM
3. Ogden Museum of Southern Art
Less than 5 minutes from the convention center, the Ogden Museum of Southern Art holds the largest and most comprehensive collection of southern art, including visual art, music, literature, and culinary heritage. If you’re in the city before or after the annual meeting, catch a guided tour on a Thursday afternoon. Tours are free with admission into the museum. Check their website for museum hours.
4. Escape My Room
Who doesn’t love a good escape room? At Escape My Room, look for clues and hints to help the DeLaporte family as you’re transported through history into the DeLaporte Family Museum. Bring your family or team in a group of up to eight, depending on the room, and see if you can solve the mystery.
5. A walking tour of the Garden District
Take a cable car a few stops to the Garden District, a historic neighborhood in New Orleans. This picturesque neighborhood showcases plantation-style mansions, streets separated by stretches of green parks, and the historic Lafayette Cemetery No. 1 and cable car line that runs along St. Charles Avenue. There are guided tours available, but you can also choose to take a self-tour of the area.
While CHEST 2019 will have your days busy, don’t forget to find time to explore entertaining, cultural, and historic places around New Orleans. Grab your friends and colleagues for some fun, and try out a few of these places!
1. House of Blues New Orleans
If you’re already heading to the city known for jazz and blues, there’s no better place to experience that than the House of Blues New Orleans. Enjoy live music and great food under one roof. Be sure to check the House of Blues website as the annual meeting draws nearer to see which concerts and events will be happening in October.
2. Audubon Aquarium of the Americas
Located just north of the convention center, head over to the Audubon Aquarium of the Americas. During the fall and winter months, the aquarium has less traffic, which allows you to take in all the animals and exhibits at your own pace. See exhibits like the Great Maya Reef, a walk-through tunnel into a submerged Maya city of the Yucatan peninsula; the penguins, sea otters, or the sharks and rays in the 400,000-gallon Gulf of Mexico Exhibit.
Hours: Monday - Sunday | 10 AM - 5 PM
3. Ogden Museum of Southern Art
Less than 5 minutes from the convention center, the Ogden Museum of Southern Art holds the largest and most comprehensive collection of southern art, including visual art, music, literature, and culinary heritage. If you’re in the city before or after the annual meeting, catch a guided tour on a Thursday afternoon. Tours are free with admission into the museum. Check their website for museum hours.
4. Escape My Room
Who doesn’t love a good escape room? At Escape My Room, look for clues and hints to help the DeLaporte family as you’re transported through history into the DeLaporte Family Museum. Bring your family or team in a group of up to eight, depending on the room, and see if you can solve the mystery.
5. A walking tour of the Garden District
Take a cable car a few stops to the Garden District, a historic neighborhood in New Orleans. This picturesque neighborhood showcases plantation-style mansions, streets separated by stretches of green parks, and the historic Lafayette Cemetery No. 1 and cable car line that runs along St. Charles Avenue. There are guided tours available, but you can also choose to take a self-tour of the area.
Check out the current CHEST Thought Leaders Blog teaser
Sleep: It Does a Body Good by Dr. Nancy Stewart
Sleep: it does a body good. No really, it does. When asked to write this month’s blog on sleep for Sleep Awareness Month, although honored, it was somewhat comical because the night prior I had one of my worst nights of sleep in a long time, taking care of a sick child. As health-care providers, we often lead stressful lives and pack way too much into our schedules. Both the Centers for Disease Control and the American Academy of Sleep Medicine recommend obtaining 7 to 9 hours of sleep per night for adults; unfortunately, many of us are not getting the recommended 7 to 9 hours of sleep.
Find the entire blog at https://goo.gl/sp9wWn.
Sleep: It Does a Body Good by Dr. Nancy Stewart
Sleep: it does a body good. No really, it does. When asked to write this month’s blog on sleep for Sleep Awareness Month, although honored, it was somewhat comical because the night prior I had one of my worst nights of sleep in a long time, taking care of a sick child. As health-care providers, we often lead stressful lives and pack way too much into our schedules. Both the Centers for Disease Control and the American Academy of Sleep Medicine recommend obtaining 7 to 9 hours of sleep per night for adults; unfortunately, many of us are not getting the recommended 7 to 9 hours of sleep.
Find the entire blog at https://goo.gl/sp9wWn.
Sleep: It Does a Body Good by Dr. Nancy Stewart
Sleep: it does a body good. No really, it does. When asked to write this month’s blog on sleep for Sleep Awareness Month, although honored, it was somewhat comical because the night prior I had one of my worst nights of sleep in a long time, taking care of a sick child. As health-care providers, we often lead stressful lives and pack way too much into our schedules. Both the Centers for Disease Control and the American Academy of Sleep Medicine recommend obtaining 7 to 9 hours of sleep per night for adults; unfortunately, many of us are not getting the recommended 7 to 9 hours of sleep.
Find the entire blog at https://goo.gl/sp9wWn.
Get ready for the Big Easy
CHEST 2019 will be in New Orleans, Louisiana, this year, October 19-23. Here are a few ways to be engaged leading up to the meeting.
Submit Abstracts and Case Reports
Do you have original investigative research to share? There’s still some time to submit your abstracts and case reports for presentation at CHEST 2019 through Friday, March 15. If accepted, all abstracts and case reports will be published as submitted in an online CHEST® journal abstract supplement. No corrections will be made once submission is complete.
View submission details (https://chestmeeting.chestnet.org/abstracts-and-case-reports/)
Call for Moderators
CHEST is currently requesting moderators to facilitate discussions, questions, and answers within assigned sessions on-site at CHEST 2019 in New Orleans. Moderators will be notified June to September of their acceptance as a moderator.
View complete details (https://docs.google.com/forms/d/e/1FAIpQLSdSWFSyKAeIjfyYgGRF6km_95znba63bx6iM9TWl08gpdqzEQ/viewform)
CHEST Challenge 2019
US-based CHEST fellows-in-training - does your fellowship have what it takes to win CHEST Challenge 2019? CHEST Challenge is a fun and exciting competition in which CHEST fellows-in-training compete against programs around the country for honor and prizes! The first round of the competition consists of two parts: social media challenges and online quiz. The aggregate score for both of these components will be used to identify the top three highest scoring teams. These top three teams will then be invited to send three fellows each to the CHEST Challenge Championship, a Jeopardy-style game show that takes place live during the CHEST Annual Meeting.
See the rules and how to participate. (chestchallenge.org)
Apply for CHEST Foundation Grants
The CHEST Foundation has awarded more than $10 million in grant funding to nearly 800 recipients worldwide for clinical research and community service. Each year, the CHEST Foundation offers grants to worthy research candidates, generous community service volunteers, and distinguished scholars in a field of expertise.
The CHEST Foundation is accepting grant applications now through April 8, 2019, in the following areas:
• CHEST Foundation Community Service Grant Honoring D. Robert McCaffree, MD, Master FCCP – Up to $15,000 (multiple recipients selected)*
• The GlaxoSmithKline Distinguished Scholar in Respiratory Health – $150,000*
• CHEST Foundation Research Grant in Asthma – $15,000 – $30,000*
• CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease – $25,000 – $50,000*
• CHEST Foundation Research Grant in Cystic Fibrosis – $15,000 – $30,000*
• CHEST Foundation Research Grant in Lung Cancer – $50,000 – $100,000*
• CHEST Foundation Research Grant in Nontuberculous Mycobacteria Diseases – $30,000 – $60,000*
• CHEST Foundation Research Grant in Pulmonary Arterial Hypertension – $25,000 – $50,000*
• CHEST Foundation Research Grant in Pulmonary Fibrosis – $25,000 – $50,000*
• CHEST Foundation Research Grant in Venous Thromboembolism – $15,000 – $30,000*
• CHEST Foundation Research Grant in Women’s Lung Health – $10,000*
*Amount contingent on funding.
Learn more on how to apply now. (https://foundation.chestnet.org/grants/apply-for-a-grant/)
CHEST 2019 will be in New Orleans, Louisiana, this year, October 19-23. Here are a few ways to be engaged leading up to the meeting.
Submit Abstracts and Case Reports
Do you have original investigative research to share? There’s still some time to submit your abstracts and case reports for presentation at CHEST 2019 through Friday, March 15. If accepted, all abstracts and case reports will be published as submitted in an online CHEST® journal abstract supplement. No corrections will be made once submission is complete.
View submission details (https://chestmeeting.chestnet.org/abstracts-and-case-reports/)
Call for Moderators
CHEST is currently requesting moderators to facilitate discussions, questions, and answers within assigned sessions on-site at CHEST 2019 in New Orleans. Moderators will be notified June to September of their acceptance as a moderator.
View complete details (https://docs.google.com/forms/d/e/1FAIpQLSdSWFSyKAeIjfyYgGRF6km_95znba63bx6iM9TWl08gpdqzEQ/viewform)
CHEST Challenge 2019
US-based CHEST fellows-in-training - does your fellowship have what it takes to win CHEST Challenge 2019? CHEST Challenge is a fun and exciting competition in which CHEST fellows-in-training compete against programs around the country for honor and prizes! The first round of the competition consists of two parts: social media challenges and online quiz. The aggregate score for both of these components will be used to identify the top three highest scoring teams. These top three teams will then be invited to send three fellows each to the CHEST Challenge Championship, a Jeopardy-style game show that takes place live during the CHEST Annual Meeting.
See the rules and how to participate. (chestchallenge.org)
Apply for CHEST Foundation Grants
The CHEST Foundation has awarded more than $10 million in grant funding to nearly 800 recipients worldwide for clinical research and community service. Each year, the CHEST Foundation offers grants to worthy research candidates, generous community service volunteers, and distinguished scholars in a field of expertise.
The CHEST Foundation is accepting grant applications now through April 8, 2019, in the following areas:
• CHEST Foundation Community Service Grant Honoring D. Robert McCaffree, MD, Master FCCP – Up to $15,000 (multiple recipients selected)*
• The GlaxoSmithKline Distinguished Scholar in Respiratory Health – $150,000*
• CHEST Foundation Research Grant in Asthma – $15,000 – $30,000*
• CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease – $25,000 – $50,000*
• CHEST Foundation Research Grant in Cystic Fibrosis – $15,000 – $30,000*
• CHEST Foundation Research Grant in Lung Cancer – $50,000 – $100,000*
• CHEST Foundation Research Grant in Nontuberculous Mycobacteria Diseases – $30,000 – $60,000*
• CHEST Foundation Research Grant in Pulmonary Arterial Hypertension – $25,000 – $50,000*
• CHEST Foundation Research Grant in Pulmonary Fibrosis – $25,000 – $50,000*
• CHEST Foundation Research Grant in Venous Thromboembolism – $15,000 – $30,000*
• CHEST Foundation Research Grant in Women’s Lung Health – $10,000*
*Amount contingent on funding.
Learn more on how to apply now. (https://foundation.chestnet.org/grants/apply-for-a-grant/)
CHEST 2019 will be in New Orleans, Louisiana, this year, October 19-23. Here are a few ways to be engaged leading up to the meeting.
Submit Abstracts and Case Reports
Do you have original investigative research to share? There’s still some time to submit your abstracts and case reports for presentation at CHEST 2019 through Friday, March 15. If accepted, all abstracts and case reports will be published as submitted in an online CHEST® journal abstract supplement. No corrections will be made once submission is complete.
View submission details (https://chestmeeting.chestnet.org/abstracts-and-case-reports/)
Call for Moderators
CHEST is currently requesting moderators to facilitate discussions, questions, and answers within assigned sessions on-site at CHEST 2019 in New Orleans. Moderators will be notified June to September of their acceptance as a moderator.
View complete details (https://docs.google.com/forms/d/e/1FAIpQLSdSWFSyKAeIjfyYgGRF6km_95znba63bx6iM9TWl08gpdqzEQ/viewform)
CHEST Challenge 2019
US-based CHEST fellows-in-training - does your fellowship have what it takes to win CHEST Challenge 2019? CHEST Challenge is a fun and exciting competition in which CHEST fellows-in-training compete against programs around the country for honor and prizes! The first round of the competition consists of two parts: social media challenges and online quiz. The aggregate score for both of these components will be used to identify the top three highest scoring teams. These top three teams will then be invited to send three fellows each to the CHEST Challenge Championship, a Jeopardy-style game show that takes place live during the CHEST Annual Meeting.
See the rules and how to participate. (chestchallenge.org)
Apply for CHEST Foundation Grants
The CHEST Foundation has awarded more than $10 million in grant funding to nearly 800 recipients worldwide for clinical research and community service. Each year, the CHEST Foundation offers grants to worthy research candidates, generous community service volunteers, and distinguished scholars in a field of expertise.
The CHEST Foundation is accepting grant applications now through April 8, 2019, in the following areas:
• CHEST Foundation Community Service Grant Honoring D. Robert McCaffree, MD, Master FCCP – Up to $15,000 (multiple recipients selected)*
• The GlaxoSmithKline Distinguished Scholar in Respiratory Health – $150,000*
• CHEST Foundation Research Grant in Asthma – $15,000 – $30,000*
• CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease – $25,000 – $50,000*
• CHEST Foundation Research Grant in Cystic Fibrosis – $15,000 – $30,000*
• CHEST Foundation Research Grant in Lung Cancer – $50,000 – $100,000*
• CHEST Foundation Research Grant in Nontuberculous Mycobacteria Diseases – $30,000 – $60,000*
• CHEST Foundation Research Grant in Pulmonary Arterial Hypertension – $25,000 – $50,000*
• CHEST Foundation Research Grant in Pulmonary Fibrosis – $25,000 – $50,000*
• CHEST Foundation Research Grant in Venous Thromboembolism – $15,000 – $30,000*
• CHEST Foundation Research Grant in Women’s Lung Health – $10,000*
*Amount contingent on funding.
Learn more on how to apply now. (https://foundation.chestnet.org/grants/apply-for-a-grant/)
CHEST updates guidelines on PAH
The American College of Chest Physicians® (CHEST) has published updates to the evidence-based guidelines on therapy for pulmonary arterial hypertension (PAH). In the latest evidence-based guideline, Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report, experts provide 78 evidence-based recommendations for appropriate use in treating patients with PAH.
“New recommendations and ungraded consensus-based statements were developed in this update based on new studies that were published since the 2014 guidelines. In addition, an evidence-based and consensus-driven treatment algorithm was created to guide the clinician through an organized approach to management,” says CHEST Pulmonary Arterial Hypertension Guidelines Committee Co-Chair, Deborah Jo Levine, MD, FCCP.
As part of the guideline development process, the panel updated the systematic review on the same clinical questions and criteria. Based on the results of the systematic review, the panel developed two new recommendations about pharmacologic therapy for PAH:
•For treatment-naive patients with PAH who are World Health Organization (WHO) functional class II and III, we suggest initial combination therapy with ambrisentan and tadalafil to improve 6-minute walk distance (6MWD).
•For stable or symptomatic patients with PAH on background therapy with ambrisentan, we suggest the addition of tadalafil to improve 6MWD.
The complete guideline article is free to view in the Online First section of the journal CHEST®.
The American College of Chest Physicians® (CHEST) has published updates to the evidence-based guidelines on therapy for pulmonary arterial hypertension (PAH). In the latest evidence-based guideline, Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report, experts provide 78 evidence-based recommendations for appropriate use in treating patients with PAH.
“New recommendations and ungraded consensus-based statements were developed in this update based on new studies that were published since the 2014 guidelines. In addition, an evidence-based and consensus-driven treatment algorithm was created to guide the clinician through an organized approach to management,” says CHEST Pulmonary Arterial Hypertension Guidelines Committee Co-Chair, Deborah Jo Levine, MD, FCCP.
As part of the guideline development process, the panel updated the systematic review on the same clinical questions and criteria. Based on the results of the systematic review, the panel developed two new recommendations about pharmacologic therapy for PAH:
•For treatment-naive patients with PAH who are World Health Organization (WHO) functional class II and III, we suggest initial combination therapy with ambrisentan and tadalafil to improve 6-minute walk distance (6MWD).
•For stable or symptomatic patients with PAH on background therapy with ambrisentan, we suggest the addition of tadalafil to improve 6MWD.
The complete guideline article is free to view in the Online First section of the journal CHEST®.
The American College of Chest Physicians® (CHEST) has published updates to the evidence-based guidelines on therapy for pulmonary arterial hypertension (PAH). In the latest evidence-based guideline, Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report, experts provide 78 evidence-based recommendations for appropriate use in treating patients with PAH.
“New recommendations and ungraded consensus-based statements were developed in this update based on new studies that were published since the 2014 guidelines. In addition, an evidence-based and consensus-driven treatment algorithm was created to guide the clinician through an organized approach to management,” says CHEST Pulmonary Arterial Hypertension Guidelines Committee Co-Chair, Deborah Jo Levine, MD, FCCP.
As part of the guideline development process, the panel updated the systematic review on the same clinical questions and criteria. Based on the results of the systematic review, the panel developed two new recommendations about pharmacologic therapy for PAH:
•For treatment-naive patients with PAH who are World Health Organization (WHO) functional class II and III, we suggest initial combination therapy with ambrisentan and tadalafil to improve 6-minute walk distance (6MWD).
•For stable or symptomatic patients with PAH on background therapy with ambrisentan, we suggest the addition of tadalafil to improve 6MWD.
The complete guideline article is free to view in the Online First section of the journal CHEST®.
CHEST reaccredited by Society for Simulation in Healthcare
The American College of Chest Physicians (CHEST) received reaccreditation from the Society for Simulation in Healthcare (SSH) for the 2018-2023 term in the areas of Teaching/Education, Assessment, and Research. In 2013, CHEST became the first and only medical specialty society to achieve SSH accreditation, a distinction that continues today. Currently, CHEST joins over 125 SSH-accredited programs worldwide, including universities, hospitals, and medical education companies.
The reaccreditation process was the result of months of preparation on behalf of CHEST Simulation Program staff, CHEST Accreditation staff, CHEST Outcomes staff, as well as CHEST’s Live Learning Domain Task Force chairs and other education leadership. This culminated in mid-November at a face-to-face on-site interview with site reviewers representing SSH and CHEST Simulation Program faculty and staff and CHEST leadership. Throughout the process, CHEST was given the opportunity to highlight the unique and innovative ways in which we are utilizing simulation-based education to provide greater clinical insights to enhance patient care.
We recognize that this isn’t only an every-4-year commitment, but it is resultant of the ongoing efforts from a group of dedicated individuals. Thank you to all whose contributions ensured our success!
The American College of Chest Physicians (CHEST) received reaccreditation from the Society for Simulation in Healthcare (SSH) for the 2018-2023 term in the areas of Teaching/Education, Assessment, and Research. In 2013, CHEST became the first and only medical specialty society to achieve SSH accreditation, a distinction that continues today. Currently, CHEST joins over 125 SSH-accredited programs worldwide, including universities, hospitals, and medical education companies.
The reaccreditation process was the result of months of preparation on behalf of CHEST Simulation Program staff, CHEST Accreditation staff, CHEST Outcomes staff, as well as CHEST’s Live Learning Domain Task Force chairs and other education leadership. This culminated in mid-November at a face-to-face on-site interview with site reviewers representing SSH and CHEST Simulation Program faculty and staff and CHEST leadership. Throughout the process, CHEST was given the opportunity to highlight the unique and innovative ways in which we are utilizing simulation-based education to provide greater clinical insights to enhance patient care.
We recognize that this isn’t only an every-4-year commitment, but it is resultant of the ongoing efforts from a group of dedicated individuals. Thank you to all whose contributions ensured our success!
The American College of Chest Physicians (CHEST) received reaccreditation from the Society for Simulation in Healthcare (SSH) for the 2018-2023 term in the areas of Teaching/Education, Assessment, and Research. In 2013, CHEST became the first and only medical specialty society to achieve SSH accreditation, a distinction that continues today. Currently, CHEST joins over 125 SSH-accredited programs worldwide, including universities, hospitals, and medical education companies.
The reaccreditation process was the result of months of preparation on behalf of CHEST Simulation Program staff, CHEST Accreditation staff, CHEST Outcomes staff, as well as CHEST’s Live Learning Domain Task Force chairs and other education leadership. This culminated in mid-November at a face-to-face on-site interview with site reviewers representing SSH and CHEST Simulation Program faculty and staff and CHEST leadership. Throughout the process, CHEST was given the opportunity to highlight the unique and innovative ways in which we are utilizing simulation-based education to provide greater clinical insights to enhance patient care.
We recognize that this isn’t only an every-4-year commitment, but it is resultant of the ongoing efforts from a group of dedicated individuals. Thank you to all whose contributions ensured our success!
In Memoriam
CHEST has been notified of the following deaths.
We extend our sincere condolences.
Faroque A. Khan, MBBS
Venessa Holland, MD, FCCP
CHEST has been notified of the following deaths.
We extend our sincere condolences.
Faroque A. Khan, MBBS
Venessa Holland, MD, FCCP
CHEST has been notified of the following deaths.
We extend our sincere condolences.
Faroque A. Khan, MBBS
Venessa Holland, MD, FCCP
This Month in CHEST: Editor’s picks
Giants in Chest Medicine – Paul D. Stein, MD, Master FCCP’
Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials. By Dr. E. J. Schenck, et al.
The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis
Based on Individual Participant Data. By Dr. N. Navani, et al.
A Simple Clinical Risk Score (C2HEST) for Predicting Incident Atrial Fibrillation in Asian
Subjects: Derivation in 471,446 Chinese Subjects, With Internal Validation and External
Application in 451,199 Korean Subjects. By Dr. Y-G Li, et al.
A Sleep Medicine Curriculum for Pulmonary and Pulmonary/Critical Care Fellowship
Programs: A Multisociety Expert Panel Report. By Dr. D. A. Schulman, et al.
Giants in Chest Medicine – Paul D. Stein, MD, Master FCCP’
Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials. By Dr. E. J. Schenck, et al.
The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis
Based on Individual Participant Data. By Dr. N. Navani, et al.
A Simple Clinical Risk Score (C2HEST) for Predicting Incident Atrial Fibrillation in Asian
Subjects: Derivation in 471,446 Chinese Subjects, With Internal Validation and External
Application in 451,199 Korean Subjects. By Dr. Y-G Li, et al.
A Sleep Medicine Curriculum for Pulmonary and Pulmonary/Critical Care Fellowship
Programs: A Multisociety Expert Panel Report. By Dr. D. A. Schulman, et al.
Giants in Chest Medicine – Paul D. Stein, MD, Master FCCP’
Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials. By Dr. E. J. Schenck, et al.
The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis
Based on Individual Participant Data. By Dr. N. Navani, et al.
A Simple Clinical Risk Score (C2HEST) for Predicting Incident Atrial Fibrillation in Asian
Subjects: Derivation in 471,446 Chinese Subjects, With Internal Validation and External
Application in 451,199 Korean Subjects. By Dr. Y-G Li, et al.
A Sleep Medicine Curriculum for Pulmonary and Pulmonary/Critical Care Fellowship
Programs: A Multisociety Expert Panel Report. By Dr. D. A. Schulman, et al.
Disaster response, practice operations, transplant, women's health
Disaster Response and Global Health
Epigenetics and Disasters
The configuration of the DNA bordering a gene dictates under what conditions a gene is expressed. Random errors or mutations affecting the neighboring DNA or the gene itself can affect how the gene functions. Epigenetics is an emerging field of science looking at environmental and psychosocial factors that do not directly cause mutations but still affect how genes are expressed with implications for the development and inheritance of disease. These external influences are thought to affect why some segments of DNA become accessible for protein production while other segments may not.
Disasters represent stressors with potential for epigenetic impact. Women who were pregnant during the 1998 Quebec ice storm were found to have a correlation between maternal objective stress and a distinctive pattern of DNA methylation in their children 13 years later (Cao-Lei L, et al. PLoS ONE. 2014;9[9] e10765). Methylation is known to affect the activity of a DNA segment and how genes are expressed. Associations have also been found between the severity of hurricanes and the prevalence of autism in the offspring of pregnant women experiencing these disasters (Kinney DK, et al. J Autism Dev Disord. 2008;38:481).
Anthropogenic hazards may also affect the offspring of survivors as suggested by studies of civil war POWs and Dutch Hunger Winter during WW II (Costa, DL, et al. Proc Nat Acad Sci 2018;. 115:44; Heijmans BT et al. Proc Nat Acad Sci. 2008;105[44]: 17046-9).
Epigenetics represents an area for additional research as natural and man-made disasters increase.
Omesh Toolsie, MBBS
Steering Committee Fellow-in-Training
Practice Operations
Medicare Competitive Bidding Process Update
Medicare’s Competitive Bidding Program (CBP), mandated since 2003, asks providers of specific durable medical equipment (including oxygen) to submit competing proposals for services. The best offer is then awarded a 3-year contract. Recently, several reforms to CBP have been proposed. The payment structure has changed to “lead-item pricing,” where a single bid in each category is selected and payment amounts for each product are then calculated based on pricing ratios and fee schedules (CMS DMEPOS Competitive Bidding).
This is in contrast to the prior method of median pricing, which caused financial difficulty and access concerns (Council for Quality Respiratory Care. The Rationale for Reforming Medicare Home Respiratory Therapy Payment Methodology. 2018). Budget neutrality requirements should relax, and oxygen payment structures improve. These proposed changes also include improved coverage of liquid oxygen and addition of home ventilator supplies.
However, effective January 1, 2019, all CBP is suspended through CMS. During the anticipated 2-year gap, any Medicare-enrolled supplier will be able to provide items until new contracts are awarded. Pricing during the gap period is based on a current single price plus consumer price index. These changes will impact CHEST members and their patients moving forward. During the temporary gap period, some areas are seeing decreased accessibility of some DME due to demand. Once reinstated, the changes to the oxygen payment structure should improve access and reduce out-of-pocket costs. The Practice Operations NetWork will continue to provide updates on this topic as they become available.
Timothy Dempsey, MD, MPH
Steering Committee Fellow-in-Training
Megan Sisk, DO
Steering Committee Member
Transplant
Medicare Part D Plans Can Deny Coverage of Select Immunosuppressant Medications in Solid Organ Transplant Recipients
An alarming problem has emerged with some solid organ transplant recipients experiencing immunosuppressant medication claim denials by Medicare Part D plans. Affected patients are those who convert from some other insurance (ie, private insurance or state Medicaid) to Medicare after their transplant and, therefore, rely on Medicare Part D for immunosuppressant drug coverage.
Insurance companies who offer Medicare Part D plans must follow the rules described in the Medicare Prescription Drug Benefit Manual.1 Although the Manual mandates that all immunosuppressant medications are on plan formularies, Part D plans are only required to cover immunosuppressant medications when used for indications approved by the Food and Drug Administration (FDA) or for off-label indications supported by the Centers for Medicare & Medicaid Services (CMS)-approved compendia (Drugdex® and AHFS Drug Information®).
A recent study examining the extent of the problem demonstrated non-renal organ transplant recipients are frequently prescribed and maintained on at least one medication vulnerable to Medicare Part D claim denials at 1 year posttransplant (lung: 71.1%; intestine: 39.7%; pancreas: 36.8%; liver: 19.7%; heart: 18.5%).2 Lung transplant recipients are most vulnerable since no immunosuppressant is FDA-approved for use in lung transplantation, and CMS-approved compendia only support off-label use for tacrolimus and cyclosporine in this population. Therefore, mycophenolate mofetil, mycophenolic acid, azathioprine, everolimus, and sirolimus are vulnerable to denial by Medicare Part D plans when used in lung transplant recipients. Over 95% of lung transplant recipients are maintained on an anti-metabolite, with the majority (88%) maintained on mycophenolate, so this is frequently impacted.2,3 While the transplant community is aware of this issue and has begun work to correct it, it has yet to be solved.2,4 In the meantime, if transplant recipients have been denied for this off-label and off-compendia reason, and appeals of those decisions have also been denied, options for obtaining the denied immunosuppressant medication include discount programs, foundation/grant funding, and industry-sponsored assistance programs.
Jennifer K. McDermott, PharmD
NetWork Member
1. Prescription Drug Benefit Manual. Centers for Medicare & Medicaid Services. Chapter 6: Part D Drugs and Formulary Requirements. Available at: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Part-D-Benefits-Manual-Chapter-6.pdf
2. Potter LM et al. Transplant recipients are vulnerable to coverage denial under Medicare Part D. Am J Transplant. 2018;18:1502.
3. Valapour M et al. OPTN/SRTR 2016 Annual Data Report: Lung. Am J Transplant. 2018;18 (Suppl 1): 363.
4. Immunusuppressant Drug Coverage Under Medicare Part D Benefit. American Society of Transplantation. Available at: www.myast.org/public-policy/key-position-statements/immunosuppressant-drug-coverage-under-medicare-part-d-benefit.
Women’s Health
Cannabis Use Affects Women Differently
As we enter an era of legalization, cannabis use is increasingly prevalent. Variances in the risks for women and men have been observed. For most age groups, men have higher rates of use or dependence on illicit drugs than women. However, women are equally likely as men to progress to a substance use disorder. Women may be more susceptible to craving and relapse , which are key phases of the addiction cycle. A study on use among adolescents concluded there was preliminary evidence of a faster transition from initiation of marijuana use to regular use in women, when compared with men (Schepis, et al. J Addict Med. 2011;5[1]:65).
Research studies suggest that marijuana impairs spatial memory in women more so than in men. Studies have suggested that teenage girls who use marijuana may have a higher risk of brain structural abnormalities associated with regular marijuana exposure than teenage boys (Tapert, et al. Addict Biol. 2009;14[4]:457).
A study published in Psychoneuroendocrinology showed that cannabinoid receptor binding site densities exhibit sex differences and can be modulated by estradiol in several limbic brain regions. These findings may account for the sex differences observed with respect to the effects of cannabinoids (Riebe, et al. Psychoneuroendocrinology. 2010;35[8]:1265).
Further research is needed to expand our understanding of the interactions between cannabinoids and sex steroids. Detoxification treatments tailored toward women and men with cannabis addiction show a promising future and necessitate further research.
Anita Rajagopal, MD
Steering Committee Member
Disaster Response and Global Health
Epigenetics and Disasters
The configuration of the DNA bordering a gene dictates under what conditions a gene is expressed. Random errors or mutations affecting the neighboring DNA or the gene itself can affect how the gene functions. Epigenetics is an emerging field of science looking at environmental and psychosocial factors that do not directly cause mutations but still affect how genes are expressed with implications for the development and inheritance of disease. These external influences are thought to affect why some segments of DNA become accessible for protein production while other segments may not.
Disasters represent stressors with potential for epigenetic impact. Women who were pregnant during the 1998 Quebec ice storm were found to have a correlation between maternal objective stress and a distinctive pattern of DNA methylation in their children 13 years later (Cao-Lei L, et al. PLoS ONE. 2014;9[9] e10765). Methylation is known to affect the activity of a DNA segment and how genes are expressed. Associations have also been found between the severity of hurricanes and the prevalence of autism in the offspring of pregnant women experiencing these disasters (Kinney DK, et al. J Autism Dev Disord. 2008;38:481).
Anthropogenic hazards may also affect the offspring of survivors as suggested by studies of civil war POWs and Dutch Hunger Winter during WW II (Costa, DL, et al. Proc Nat Acad Sci 2018;. 115:44; Heijmans BT et al. Proc Nat Acad Sci. 2008;105[44]: 17046-9).
Epigenetics represents an area for additional research as natural and man-made disasters increase.
Omesh Toolsie, MBBS
Steering Committee Fellow-in-Training
Practice Operations
Medicare Competitive Bidding Process Update
Medicare’s Competitive Bidding Program (CBP), mandated since 2003, asks providers of specific durable medical equipment (including oxygen) to submit competing proposals for services. The best offer is then awarded a 3-year contract. Recently, several reforms to CBP have been proposed. The payment structure has changed to “lead-item pricing,” where a single bid in each category is selected and payment amounts for each product are then calculated based on pricing ratios and fee schedules (CMS DMEPOS Competitive Bidding).
This is in contrast to the prior method of median pricing, which caused financial difficulty and access concerns (Council for Quality Respiratory Care. The Rationale for Reforming Medicare Home Respiratory Therapy Payment Methodology. 2018). Budget neutrality requirements should relax, and oxygen payment structures improve. These proposed changes also include improved coverage of liquid oxygen and addition of home ventilator supplies.
However, effective January 1, 2019, all CBP is suspended through CMS. During the anticipated 2-year gap, any Medicare-enrolled supplier will be able to provide items until new contracts are awarded. Pricing during the gap period is based on a current single price plus consumer price index. These changes will impact CHEST members and their patients moving forward. During the temporary gap period, some areas are seeing decreased accessibility of some DME due to demand. Once reinstated, the changes to the oxygen payment structure should improve access and reduce out-of-pocket costs. The Practice Operations NetWork will continue to provide updates on this topic as they become available.
Timothy Dempsey, MD, MPH
Steering Committee Fellow-in-Training
Megan Sisk, DO
Steering Committee Member
Transplant
Medicare Part D Plans Can Deny Coverage of Select Immunosuppressant Medications in Solid Organ Transplant Recipients
An alarming problem has emerged with some solid organ transplant recipients experiencing immunosuppressant medication claim denials by Medicare Part D plans. Affected patients are those who convert from some other insurance (ie, private insurance or state Medicaid) to Medicare after their transplant and, therefore, rely on Medicare Part D for immunosuppressant drug coverage.
Insurance companies who offer Medicare Part D plans must follow the rules described in the Medicare Prescription Drug Benefit Manual.1 Although the Manual mandates that all immunosuppressant medications are on plan formularies, Part D plans are only required to cover immunosuppressant medications when used for indications approved by the Food and Drug Administration (FDA) or for off-label indications supported by the Centers for Medicare & Medicaid Services (CMS)-approved compendia (Drugdex® and AHFS Drug Information®).
A recent study examining the extent of the problem demonstrated non-renal organ transplant recipients are frequently prescribed and maintained on at least one medication vulnerable to Medicare Part D claim denials at 1 year posttransplant (lung: 71.1%; intestine: 39.7%; pancreas: 36.8%; liver: 19.7%; heart: 18.5%).2 Lung transplant recipients are most vulnerable since no immunosuppressant is FDA-approved for use in lung transplantation, and CMS-approved compendia only support off-label use for tacrolimus and cyclosporine in this population. Therefore, mycophenolate mofetil, mycophenolic acid, azathioprine, everolimus, and sirolimus are vulnerable to denial by Medicare Part D plans when used in lung transplant recipients. Over 95% of lung transplant recipients are maintained on an anti-metabolite, with the majority (88%) maintained on mycophenolate, so this is frequently impacted.2,3 While the transplant community is aware of this issue and has begun work to correct it, it has yet to be solved.2,4 In the meantime, if transplant recipients have been denied for this off-label and off-compendia reason, and appeals of those decisions have also been denied, options for obtaining the denied immunosuppressant medication include discount programs, foundation/grant funding, and industry-sponsored assistance programs.
Jennifer K. McDermott, PharmD
NetWork Member
1. Prescription Drug Benefit Manual. Centers for Medicare & Medicaid Services. Chapter 6: Part D Drugs and Formulary Requirements. Available at: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Part-D-Benefits-Manual-Chapter-6.pdf
2. Potter LM et al. Transplant recipients are vulnerable to coverage denial under Medicare Part D. Am J Transplant. 2018;18:1502.
3. Valapour M et al. OPTN/SRTR 2016 Annual Data Report: Lung. Am J Transplant. 2018;18 (Suppl 1): 363.
4. Immunusuppressant Drug Coverage Under Medicare Part D Benefit. American Society of Transplantation. Available at: www.myast.org/public-policy/key-position-statements/immunosuppressant-drug-coverage-under-medicare-part-d-benefit.
Women’s Health
Cannabis Use Affects Women Differently
As we enter an era of legalization, cannabis use is increasingly prevalent. Variances in the risks for women and men have been observed. For most age groups, men have higher rates of use or dependence on illicit drugs than women. However, women are equally likely as men to progress to a substance use disorder. Women may be more susceptible to craving and relapse , which are key phases of the addiction cycle. A study on use among adolescents concluded there was preliminary evidence of a faster transition from initiation of marijuana use to regular use in women, when compared with men (Schepis, et al. J Addict Med. 2011;5[1]:65).
Research studies suggest that marijuana impairs spatial memory in women more so than in men. Studies have suggested that teenage girls who use marijuana may have a higher risk of brain structural abnormalities associated with regular marijuana exposure than teenage boys (Tapert, et al. Addict Biol. 2009;14[4]:457).
A study published in Psychoneuroendocrinology showed that cannabinoid receptor binding site densities exhibit sex differences and can be modulated by estradiol in several limbic brain regions. These findings may account for the sex differences observed with respect to the effects of cannabinoids (Riebe, et al. Psychoneuroendocrinology. 2010;35[8]:1265).
Further research is needed to expand our understanding of the interactions between cannabinoids and sex steroids. Detoxification treatments tailored toward women and men with cannabis addiction show a promising future and necessitate further research.
Anita Rajagopal, MD
Steering Committee Member
Disaster Response and Global Health
Epigenetics and Disasters
The configuration of the DNA bordering a gene dictates under what conditions a gene is expressed. Random errors or mutations affecting the neighboring DNA or the gene itself can affect how the gene functions. Epigenetics is an emerging field of science looking at environmental and psychosocial factors that do not directly cause mutations but still affect how genes are expressed with implications for the development and inheritance of disease. These external influences are thought to affect why some segments of DNA become accessible for protein production while other segments may not.
Disasters represent stressors with potential for epigenetic impact. Women who were pregnant during the 1998 Quebec ice storm were found to have a correlation between maternal objective stress and a distinctive pattern of DNA methylation in their children 13 years later (Cao-Lei L, et al. PLoS ONE. 2014;9[9] e10765). Methylation is known to affect the activity of a DNA segment and how genes are expressed. Associations have also been found between the severity of hurricanes and the prevalence of autism in the offspring of pregnant women experiencing these disasters (Kinney DK, et al. J Autism Dev Disord. 2008;38:481).
Anthropogenic hazards may also affect the offspring of survivors as suggested by studies of civil war POWs and Dutch Hunger Winter during WW II (Costa, DL, et al. Proc Nat Acad Sci 2018;. 115:44; Heijmans BT et al. Proc Nat Acad Sci. 2008;105[44]: 17046-9).
Epigenetics represents an area for additional research as natural and man-made disasters increase.
Omesh Toolsie, MBBS
Steering Committee Fellow-in-Training
Practice Operations
Medicare Competitive Bidding Process Update
Medicare’s Competitive Bidding Program (CBP), mandated since 2003, asks providers of specific durable medical equipment (including oxygen) to submit competing proposals for services. The best offer is then awarded a 3-year contract. Recently, several reforms to CBP have been proposed. The payment structure has changed to “lead-item pricing,” where a single bid in each category is selected and payment amounts for each product are then calculated based on pricing ratios and fee schedules (CMS DMEPOS Competitive Bidding).
This is in contrast to the prior method of median pricing, which caused financial difficulty and access concerns (Council for Quality Respiratory Care. The Rationale for Reforming Medicare Home Respiratory Therapy Payment Methodology. 2018). Budget neutrality requirements should relax, and oxygen payment structures improve. These proposed changes also include improved coverage of liquid oxygen and addition of home ventilator supplies.
However, effective January 1, 2019, all CBP is suspended through CMS. During the anticipated 2-year gap, any Medicare-enrolled supplier will be able to provide items until new contracts are awarded. Pricing during the gap period is based on a current single price plus consumer price index. These changes will impact CHEST members and their patients moving forward. During the temporary gap period, some areas are seeing decreased accessibility of some DME due to demand. Once reinstated, the changes to the oxygen payment structure should improve access and reduce out-of-pocket costs. The Practice Operations NetWork will continue to provide updates on this topic as they become available.
Timothy Dempsey, MD, MPH
Steering Committee Fellow-in-Training
Megan Sisk, DO
Steering Committee Member
Transplant
Medicare Part D Plans Can Deny Coverage of Select Immunosuppressant Medications in Solid Organ Transplant Recipients
An alarming problem has emerged with some solid organ transplant recipients experiencing immunosuppressant medication claim denials by Medicare Part D plans. Affected patients are those who convert from some other insurance (ie, private insurance or state Medicaid) to Medicare after their transplant and, therefore, rely on Medicare Part D for immunosuppressant drug coverage.
Insurance companies who offer Medicare Part D plans must follow the rules described in the Medicare Prescription Drug Benefit Manual.1 Although the Manual mandates that all immunosuppressant medications are on plan formularies, Part D plans are only required to cover immunosuppressant medications when used for indications approved by the Food and Drug Administration (FDA) or for off-label indications supported by the Centers for Medicare & Medicaid Services (CMS)-approved compendia (Drugdex® and AHFS Drug Information®).
A recent study examining the extent of the problem demonstrated non-renal organ transplant recipients are frequently prescribed and maintained on at least one medication vulnerable to Medicare Part D claim denials at 1 year posttransplant (lung: 71.1%; intestine: 39.7%; pancreas: 36.8%; liver: 19.7%; heart: 18.5%).2 Lung transplant recipients are most vulnerable since no immunosuppressant is FDA-approved for use in lung transplantation, and CMS-approved compendia only support off-label use for tacrolimus and cyclosporine in this population. Therefore, mycophenolate mofetil, mycophenolic acid, azathioprine, everolimus, and sirolimus are vulnerable to denial by Medicare Part D plans when used in lung transplant recipients. Over 95% of lung transplant recipients are maintained on an anti-metabolite, with the majority (88%) maintained on mycophenolate, so this is frequently impacted.2,3 While the transplant community is aware of this issue and has begun work to correct it, it has yet to be solved.2,4 In the meantime, if transplant recipients have been denied for this off-label and off-compendia reason, and appeals of those decisions have also been denied, options for obtaining the denied immunosuppressant medication include discount programs, foundation/grant funding, and industry-sponsored assistance programs.
Jennifer K. McDermott, PharmD
NetWork Member
1. Prescription Drug Benefit Manual. Centers for Medicare & Medicaid Services. Chapter 6: Part D Drugs and Formulary Requirements. Available at: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Part-D-Benefits-Manual-Chapter-6.pdf
2. Potter LM et al. Transplant recipients are vulnerable to coverage denial under Medicare Part D. Am J Transplant. 2018;18:1502.
3. Valapour M et al. OPTN/SRTR 2016 Annual Data Report: Lung. Am J Transplant. 2018;18 (Suppl 1): 363.
4. Immunusuppressant Drug Coverage Under Medicare Part D Benefit. American Society of Transplantation. Available at: www.myast.org/public-policy/key-position-statements/immunosuppressant-drug-coverage-under-medicare-part-d-benefit.
Women’s Health
Cannabis Use Affects Women Differently
As we enter an era of legalization, cannabis use is increasingly prevalent. Variances in the risks for women and men have been observed. For most age groups, men have higher rates of use or dependence on illicit drugs than women. However, women are equally likely as men to progress to a substance use disorder. Women may be more susceptible to craving and relapse , which are key phases of the addiction cycle. A study on use among adolescents concluded there was preliminary evidence of a faster transition from initiation of marijuana use to regular use in women, when compared with men (Schepis, et al. J Addict Med. 2011;5[1]:65).
Research studies suggest that marijuana impairs spatial memory in women more so than in men. Studies have suggested that teenage girls who use marijuana may have a higher risk of brain structural abnormalities associated with regular marijuana exposure than teenage boys (Tapert, et al. Addict Biol. 2009;14[4]:457).
A study published in Psychoneuroendocrinology showed that cannabinoid receptor binding site densities exhibit sex differences and can be modulated by estradiol in several limbic brain regions. These findings may account for the sex differences observed with respect to the effects of cannabinoids (Riebe, et al. Psychoneuroendocrinology. 2010;35[8]:1265).
Further research is needed to expand our understanding of the interactions between cannabinoids and sex steroids. Detoxification treatments tailored toward women and men with cannabis addiction show a promising future and necessitate further research.
Anita Rajagopal, MD
Steering Committee Member
CHEST Foundation’s NetWorks Challenge is just around the corner
The NetWorks Challenge is an annual fundraising competition that encourages NetWork members to contribute to the CHEST Foundation - supporting clinical research grants and community service programs and creating patient education materials - while earning travel grants for their NetWork members to the CHEST Annual Meeting 2019 in New Orleans. Because of your generosity throughout the 2018 NetWorks Challenge, the CHEST Foundation was able to send 59 early career clinicians to CHEST 2018 in San Antonio - marked growth from the 25 clinicians who received the travel grants in 2017.
As we further improve this program based on feedback from NetWorks members, a few elements of the fundraiser are changing in 2019.
Length: This year, the NetWorks Challenge will span 3 months. Contributions made between April 1 and June 30 count toward your NetWork’s fundraising total! Just be sure to list your NetWork when making your contribution on chestfoundation.org/donate. Each month has a unique theme related to CHEST, so be sure to watch our social media profiles to engage with us and each other during the drive.
Additionally, ANY contributions made to the CHEST Foundation during your membership renewal will count toward your NetWorks total amount raised - no matter when your membership is up for renewal. Contributions made in this manner after June 30 will count toward your Network’s 2020 amount raised.
Prizes: This year, every NetWork is eligible to receive travel grants to CHEST 2019 in New Orleans based on the amount raised by the NetWork. Our final winners – the NetWork with the highest amount raised, and the NetWork with the highest percentage of participation from their NetWork, will each receive two additional travel grants to CHEST 2019. Plus, the NetWork with the highest amount raised over the course of the challenge receives an additional prize – a seat in a CHEST Live Learning course of the winner’s choosing, offered at CHEST’s Innovation, Simulation, and Training Center in Glenview, Illinois.
Visit chestfoundation.org/nc for more detailed information.
The NetWorks Challenge is an annual fundraising competition that encourages NetWork members to contribute to the CHEST Foundation - supporting clinical research grants and community service programs and creating patient education materials - while earning travel grants for their NetWork members to the CHEST Annual Meeting 2019 in New Orleans. Because of your generosity throughout the 2018 NetWorks Challenge, the CHEST Foundation was able to send 59 early career clinicians to CHEST 2018 in San Antonio - marked growth from the 25 clinicians who received the travel grants in 2017.
As we further improve this program based on feedback from NetWorks members, a few elements of the fundraiser are changing in 2019.
Length: This year, the NetWorks Challenge will span 3 months. Contributions made between April 1 and June 30 count toward your NetWork’s fundraising total! Just be sure to list your NetWork when making your contribution on chestfoundation.org/donate. Each month has a unique theme related to CHEST, so be sure to watch our social media profiles to engage with us and each other during the drive.
Additionally, ANY contributions made to the CHEST Foundation during your membership renewal will count toward your NetWorks total amount raised - no matter when your membership is up for renewal. Contributions made in this manner after June 30 will count toward your Network’s 2020 amount raised.
Prizes: This year, every NetWork is eligible to receive travel grants to CHEST 2019 in New Orleans based on the amount raised by the NetWork. Our final winners – the NetWork with the highest amount raised, and the NetWork with the highest percentage of participation from their NetWork, will each receive two additional travel grants to CHEST 2019. Plus, the NetWork with the highest amount raised over the course of the challenge receives an additional prize – a seat in a CHEST Live Learning course of the winner’s choosing, offered at CHEST’s Innovation, Simulation, and Training Center in Glenview, Illinois.
Visit chestfoundation.org/nc for more detailed information.
The NetWorks Challenge is an annual fundraising competition that encourages NetWork members to contribute to the CHEST Foundation - supporting clinical research grants and community service programs and creating patient education materials - while earning travel grants for their NetWork members to the CHEST Annual Meeting 2019 in New Orleans. Because of your generosity throughout the 2018 NetWorks Challenge, the CHEST Foundation was able to send 59 early career clinicians to CHEST 2018 in San Antonio - marked growth from the 25 clinicians who received the travel grants in 2017.
As we further improve this program based on feedback from NetWorks members, a few elements of the fundraiser are changing in 2019.
Length: This year, the NetWorks Challenge will span 3 months. Contributions made between April 1 and June 30 count toward your NetWork’s fundraising total! Just be sure to list your NetWork when making your contribution on chestfoundation.org/donate. Each month has a unique theme related to CHEST, so be sure to watch our social media profiles to engage with us and each other during the drive.
Additionally, ANY contributions made to the CHEST Foundation during your membership renewal will count toward your NetWorks total amount raised - no matter when your membership is up for renewal. Contributions made in this manner after June 30 will count toward your Network’s 2020 amount raised.
Prizes: This year, every NetWork is eligible to receive travel grants to CHEST 2019 in New Orleans based on the amount raised by the NetWork. Our final winners – the NetWork with the highest amount raised, and the NetWork with the highest percentage of participation from their NetWork, will each receive two additional travel grants to CHEST 2019. Plus, the NetWork with the highest amount raised over the course of the challenge receives an additional prize – a seat in a CHEST Live Learning course of the winner’s choosing, offered at CHEST’s Innovation, Simulation, and Training Center in Glenview, Illinois.
Visit chestfoundation.org/nc for more detailed information.